Pyxis Oncology, Inc.
HealthcareNASDAQ:PYXS · NASDAQ Global Select
+$0.09 today
Vol 0.44M · Avg 0.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.1%
avg -28.2%
ROIC
-117.1%
avg -75.2%
ROA
-87.0%
avg -57.6%
Analysis
ROA is currently the strongest return metric at -87.0% versus its period average of -57.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial Officer | $559,050.00 | — | 45 | $512,882.00 | 0.81% |
Thomas Civik | Interim CEO & Director | $47,500.00 | — | 57 | $690,131.00 | 1.09% |
Shui He | Head of Biometrics | — | — | — | — | — |
Donna Regalado | Head of Human Resources | — | — | — | — | — |
Balu N. Balasubramanian | Interim Chief Technology Officer | — | — | — | — | — |
Charles T. Gombar | Senior Vice President of Portfolio & Program Management | — | — | — | — | — |
Chris Cohen | Head of Drug Safety & Pharmacovigilance | — | — | — | — | — |
Hongwei Wang | Head of ADC Development & Clinical Strategy | — | — | — | — | — |
Jan Pinkas | Chief Scientific Officer | — | — | 57 | — | — |
Michael Bui | Senior Vice President of Global Regulatory Affairs | — | — | — | $45,867.00 | 0.07% |
Supriya Roth | Head of Commercial Development | — | — | — | — | — |
Alex Kane | Senior Vice President of Investor Relations & Capital Markets | — | — | — | — | — |
Marsha Crochiere | Head of Translational Medicine & Research | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Who manages PYXS?
Pyxis Oncology, Inc. (PYXS) lists 13 active executives. The top listed executive is Shui He, Head of Biometrics.
Are PYXS insiders buying or selling?
Recent insider activity shows net buying of $40.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.